Everest Medicines and Singapore's EDDC Enters into a Global Licensing Agreement to Develop and Commercialize EDDC’s 3CL Protease Inhibitors as COVID-19 Oral Antiviral Treatments Worldwide
- EDDC will receive an initial upfront payment and downstream clinical and commercial milestone payments, along with royalties on net product sales. Everest holds full rights to sub-license EDDC-2214 and will also receive full technology transfer
- Everest will get exclusive global rights to EDDC's series of 3CL protease inhibitors that demonstrated potent in-vitro activity against SAR-CoV-2 and its variants, as well as other coronaviruses like MERS.
- EDDC-2214 is a novel and potent SARS-CoV-2 3CL protease inhibitor which exhibits better in-vitro potency and pre-clinical oral bioavailability as compared to other oral COVID-19 antivirals. The clinical trials evaluating EDDC-2214 are anticipated to initiate later in 2022
Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]